Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience

被引：0

作者：

Seiwerth, Fran ^{[1
]}

Bitar, Lela ^{[1
]}

Markelic, Ivona ^{[1
]}

Dzubur, Fedza ^{[1
]}

Brcic, Luka ^{[2
]}

Seiwerth, Sven ^{[3
]}

Misic, Marija ^{[3
]}

Roglic, Mihovil ^{[1
]}

Plestina, Sanja ^{[1
]}

Cucevic, Branka ^{[1
]}

Kukulj, Suzana ^{[1
]}

Smojver-Jezek, Silvana ^{[1
]}

Samarzija, Miroslav ^{[1
]}

Jakopovic, Marko ^{[1
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Resp Dis Jordanovac, Zagreb, Croatia

[2] Med Univ Graz, Inst Pathol, Graz, Austria

[3] Univ Zagreb, Sch Med, Dept Pathol, Zagreb, Croatia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

EGFR;

D O I：

10.1016/j.jtho.2016.11.1782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-114

引用

页码：S1262 / S1262

页数：1

共 50 条

[31] MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
Ju, Lixia
Han, Mingquan
Li, Xuefei
Zhao, Chao
JOURNAL OF CANCER, 2017, 8 (07): : 1311 - 1318
[32] Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report
Luo, Yawen
Lin, Lin
Shufeng, Chen
Liu, Chun
Li, Zhuanghua
Liu, Kejun
ONCOLOGY LETTERS, 2024, 28 (05)
[33] Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung
Sing, Ng Kwok
Sun, Chu King
Ting, Kung Boom
Kun, Au Yong Ting
EUROPEAN JOURNAL OF RADIOLOGY, 2020, 123
[34] Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
Soh, Junichi
Toyooka, Shinichi
Matsuo, Keitaro
Yamamoto, Hiromasa
Wistuba, Ignacio I.
Lam, Stephen
Fong, Kwun M.
Gazdar, Adi F.
Miyoshi, Shinichiro
ONCOLOGY LETTERS, 2015, 10 (03) : 1775 - 1782
[35] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
Eun Young Kim
Arum Kim
Gaeun Lee
Hangsuck Lee
Yoon Soo Chang
BMC Cancer, 18
[36] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
Kim, Eun Young
Kim, Arum
Lee, Gaeun
Lee, Hangsuck
Chang, Yoon Soo
BMC CANCER, 2018, 18
[37] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
Bowles, D. W.
Weickhardt, A.
Jimeno, A.
DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
[38] Immunohistochemistry Profile Predicts EGFR Mutation Status in Lung Adenocarcinoma
Li, Wencheng
Niehaus, Angela G.
O'Neill, Stacey S.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2020, 28 (05) : 502 - 506
[39] Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Ladanyi, Marc
Pao, William
MODERN PATHOLOGY, 2008, 21 : S16 - S22
[40] Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Torasawa, Masahiro
Yoshida, Tatsuya
Shiraishi, Kouya
Yagishita, Shigehiro
Ono, Hanako
Uehara, Yuji
Miyakoshi, Jun
Tateishi, Akiko
Igawa, Yukiko Shimoda
Higashiyama, Ryoko Inaba
Mochizuki, Akifumi
Masuda, Ken
Matsumoto, Yuji
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Hamamoto, Ryuji
Yamamoto, Noboru
Watanabe, Shun-ichi
Yatabe, Yasushi
Takahashi, Kazuhisa
Kohno, Takashi
Ohe, Yuichiro
LUNG CANCER, 2025, 202

← 1 2 3 4 5 →